Consolidated Statements of Operations (Unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:
Product sales	$ 76,297	$ 54,011	$ 172,252	$ 141,529
Contracts and grants	12,805	12,581	42,386	45,753
Total revenues	89,102	66,592	214,638	187,282
Operating expenses:
Cost of product sales	20,063	10,230	42,706	30,927
Research and development	28,937	27,390	89,939	84,281
Selling, general and administrative	21,955	19,155	62,484	56,542
Impairment of in-process research and development	0	0	0	9,600
Income from operations	18,147	9,817	19,509	5,932
Other income (expense):
Interest income	88	55	121	103
Interest expense	0	0	(14)	0
Other income (expense), net	58	(16)	93	1,745
Total other income (expense)	146	39	200	1,848
Income before provision for income taxes	18,293	9,856	19,709	7,780
Provision for income taxes	4,802	4,236	4,667	4,639
Net income	13,491	5,620	15,042	3,141
Net loss attributable to noncontrolling interest	0	997	871	4,276
Net income attributable to Emergent BioSolutions Inc.	$ 13,491	$ 6,617	$ 15,913	$ 7,417
Income per share - basic	$ 0.37	$ 0.18	$ 0.44	$ 0.21
Income per share - diluted	$ 0.36	$ 0.18	$ 0.44	$ 0.20
Weighted-average number of shares - basic	36,272,579	36,202,801	36,129,183	36,144,242
Weighted-average number of shares - diluted	37,015,529	36,670,094	36,504,230	36,424,630